Pharmaceutical nanotechnology zidovudine-loaded PLA and PLA-PEG blend nanoparticles: Influence of polymer type on phagocytic uptake by polymorphonuclear cells

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 257-267

  Mainardes, Rubiana Mara ^a   Gremião, Maria Palmira Daflon ^b   Brunetti, Iguatemy Lourenço ^b   Luiz Fonseca, Marcos Da ^b   Khalil, Najeh Maissar ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Chemiluminescence; Nanoparticles; Phagocytosis; Zidovudine

Indexed keywords

LUMINOL; MACROGOL; NANOPARTICLE; POLYLACTIC ACID; POLYMER; ZIDOVUDINE; MACROGOL DERIVATIVE; POLYESTER; POLYLACTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG UPTAKE; IMMUNOPATHOGENESIS; IN VITRO STUDY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PERITONEAL EXUDATE CELL; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; RAT; STEREOCHEMISTRY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; NEUTROPHIL; PHAGOCYTE; PHYSIOLOGY;

ANIMALS; NANOPARTICLES; NEUTROPHILS; PARTICLE SIZE; PHAGOCYTES; PHAGOCYTOSIS; POLYESTERS; POLYETHYLENE GLYCOLS; POLYMERS; RATS; ZIDOVUDINE;

EID: 58149267686     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21406     Document Type: Article

References (30)

1. Gref R, Luck M, Quellec P, Marchand M, Del-lacherie E, Harnisch S, Blunk T, Muller RH. 2000. "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytie uptake and plasma protein adsorption. Col Surf B Bio-interfaces 18:301-313.
2. Bazile D, Prudhomme C, Bassoullet MT, Spenle-hauer G, Veillard M. 1995. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84:493-498.
3. Tang L, Lucas AH, Eaton JW. 1993. Inflammatory responses to implanted polymeric biomaterials: Role of surface-adsorbed immunoglobulin. J Laboratory Clin Med 122:292-300.
4. Lee JH, Kopeckova P, Kopecek J, Andrade JD. 1990. Surface properties of copolymers of alkyl methacrylates with, methoxy (polyethylene oxide) metacrylates and their application as protein-resistant coatings. Biomaterials 11:455-464.
5. Bergstrom K, Osterberg E, Holmberg K, Hoffman AS, Schuman TP, Kozlowski A, Harris JM. 1994. Effects of branching and molecular weight of surface-bound poly(ethylene oxide) on protein rejection. J Biomat Sci Polymer 6:123- 132.
6. Klecker R, Collins J, Yarchoan R, Thomas R, Jenkins JF, Broder S, Myers CE. 1987. Plasma and cerebrospinal fluid pharmacokineties of 3-azido-3-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 41:407-412.
7. Richman DD, Fischl MA, Grieco MH, Gottliab MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:192-197.
8. Lutton JD, Mathew A, Levere RD, Abraham NG. 1990. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol 35: 1-5.
9. Chow F-PR, Hamburger AW. 1991. In vivo evaluation of the anemia induced by azidothymidine (AZT) in a murine model of AID. Eur J Haematol 47:91- 97.
10. Colson ER, Horwitz RI, Bia FJ, Viscoli CM. 1991. Zidovudine (AZT) for the treatment of patients infected with human immunodeficiency virus type 1. An evaluation of effectiveness in clinical practice. Arch Intern Med 151:709- 713.
11. Phillips NC, Tsoukas C. 1992. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79:1137-1143.
12. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. 1998. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 50:31-40.
13. Jackson JK, Springate CMK, Hunter WL, Burt HM. 2000. Neutrophil activation by plasma opsonized polymeric microspheres: Inhibitory effect of Pluronic F127. Biomaterials 21:1483-1491.
14. Prior P, Gander B, Blarer N, Merkle HP, Subirá ML, Irache JM, Gamazo C. 2002. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) micro-spheres. Eur J Pharm Sci 15:197-207.
15. Roser M, Fisher D, Kissel T. 1998. Surface-modified biodegradable albumin nano-and microspheres II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46:255-263.
16. Leroux JC, De Jeghere F, Annes B, Doelker E, Gumy R. 1995. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(lactic acid) nanoparticles by human monocytes. Life Sciences 57:695-703.
17. Owens DE, Peppas NA. 2006. Opsonization, biodistribution and pharmacokinetics of polymeric nano-particles. Int J Pharm 307:93-102.
18. Dahlgren C, Karlsson A. 1999. Respiratory burst in human neutrophils. J Immunol Methods 232:3-14.
19. Andrews PC, Krinsky NI. 1991. A kinetic analysis of the interactions of human myeloperoxidase with hydrogen peroxide, chloride ions, and protons. J Biol Chem 257:13240-13245.
20. Storm G, Belliot SO, Daemen T, Lasic DD. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev 17:31-48.
21. Stolnik S, Illum L, Davies SS. 1995. Long circulating microparticulate drug carriers. Adv Drug Del Rev 16:195-214.
22. Verrecchia T, Spenlehauer G, Bazile DV, Murry Brelier A, Archimbaud Y, Beillard M. 1995. Non-stealth (poly(lactic acid/albumin)) and stealth (poly (lactic acid-polyethylene glyeol)) nanoparticles as injectable drug carriers. J Control Release 36:49- 61.
23. McGann KA, Collman R, Kolson DL, Gonzalez-Scarano F, Coukos FG, Coutifaris C, Strauss JF, Natahnson N. 1994. Human immunodeficiency virus-I causes productive infections of macrophages in primary placental cell culture. J Infect Dir 169: 746-753.
24. Milman G, Sharma O.1994. Mechanism of HIV/SIV mucosal transmission. AIDS Res Hum Retroviruses 109:1305-1312.
25. Vanct-Wout AB, Kootstra NA, Mulder-Kampinga GA. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type I infections after sexual, parenteral and vertical transmission. J Clin Invest 94:2060-2067.
26. Torrence PT, Kinjo J, Lesiak K, Balzarini J, DeClerq E. 1988. AIDS dementia: Synthesis and properties of a derivative of 3-azido-3-deoxythimi-dine (AZT) that may became "locked" in the central nervous system. FEBS Lett 234:135-140.
27. Brewster ME, Anderson W, Bodor N. 1991. Brain, blood, and cerebrospinal fluid distribution of a zidovudina chemical delivery system in rabbits. J Pharm Sci 80:843-845.
28. Mizrachi Y, Rubistein A, Harish Z, Biegon A, Anderson WR, Brewster ME. 1995. Improved delivery and in vitro activity of zidovudine through the use of a redox chemical delivery system, AIDS 9:153-158
29. Bender A, SchaferV, Steffan A, Royer C, Kreuter J, Rubsamen-Waigmann H, Von Briesen H. 1994. Inhibition of HIV in vitro by antiviral drug targeting using nanoparticles. Res Virol 145:215-220.
30. Bender A, Von Briesen H, Kreuter J, Ducan IB, Rubsamen-Waigmann H. 1996. Efficiency of nano-particles as carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 40:1467-1471.